These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15569962)

  • 1. Is lipid-lowering therapy underused by African Americans at high risk of coronary heart disease within the VA health care system?
    Woodard LD; Kressin NR; Petersen LA
    Am J Public Health; 2004 Dec; 94(12):2112-7. PubMed ID: 15569962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disparities in lipid management for African Americans and Caucasians with coronary artery disease: a national cross-sectional study.
    Massing MW; Foley KA; Carter-Edwards L; Sueta CA; Alexander CM; Simpson RJ
    BMC Cardiovasc Disord; 2004 Aug; 4():15. PubMed ID: 15317654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major CHD risk factors predominate among African-American women who are eligible for lipid-lowering drug therapy under the new ATP III guidelines.
    Koro CE; L'italien GJ; Fedder DO
    Eur J Cardiovasc Prev Rehabil; 2004 Oct; 11(5):376-81. PubMed ID: 15616409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group.
    Schrott HG; Bittner V; Vittinghoff E; Herrington DM; Hulley S
    JAMA; 1997 Apr 23-30; 277(16):1281-6. PubMed ID: 9109465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Underutilization of lipid-lowering therapy in coronary artery disease.
    Batalla A; Hevia S; Reguero JR; Cubero GI
    Arch Intern Med; 2000 Sep; 160(17):2683-4. PubMed ID: 10999994
    [No Abstract]   [Full Text] [Related]  

  • 6. Rationale, design, and baseline results of the Pravastatin-to-Simvastatin Conversion Lipid Optimization Program (PSCOP).
    Ito MK; Stolley SN; Morreale AP; Lin JC; Marcus DB
    Am J Health Syst Pharm; 1999 Jun; 56(11):1107-13. PubMed ID: 10385458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey.
    Park JE; Chiang CE; Munawar M; Pham GK; Sukonthasarn A; Aquino AR; Khoo KL; Chan HW
    Eur J Prev Cardiol; 2012 Aug; 19(4):781-94. PubMed ID: 21450606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centre.
    Chan RH; Chan PH; Chan KK; Lam SC; Hai JJ; Wong MK; Tam FC; Lam L; Chan CW; Lam YM; Siu DC; Tse HF; Lee SW
    Hong Kong Med J; 2012 Oct; 18(5):395-406. PubMed ID: 23018067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals.
    Schectman G; Hiatt J
    Am J Med; 1996 Feb; 100(2):197-204. PubMed ID: 8629655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of smoking cessation interventions and aspirin for secondary prevention: are there racial disparities?
    Ambriz EH; Woodard LD; Kressin NR; Petersen LA
    Am J Med Qual; 2004; 19(4):166-71. PubMed ID: 15368781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial.
    Nyman JA; Martinson MS; Nelson D; Nugent S; Collins D; Wittes J; Fye CL; Wilt TJ; Robins SJ; Bloomfield Rubins H;
    Arch Intern Med; 2002 Jan; 162(2):177-82. PubMed ID: 11802751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors, barriers, and facilitators of lipid-lowering medication use among African Americans in a primary care clinic.
    Schwartz KL; Dailey R; Bartoces M; Binienda J; Archer C; Neale AV
    J Natl Med Assoc; 2009 Sep; 101(9):944-52. PubMed ID: 19806853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary prevention in a cardiology group practice and hospital setting after a heart-care initiative.
    LaBresh KA; Owen P; Alteri C; Reilly S; Albright PS; Hordes AR; Shaftel PA; Noonan TE; Stoukides CA; Kaul AF
    Am J Cardiol; 2000 Feb; 85(3A):23A-29A. PubMed ID: 10695704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Racial differences in compliance with NCEP-II recommendations for secondary prevention at a Veterans Affairs medical center.
    Williams ML; Morris MT; Ahmad U; Yousseff M; Li W; Ertel N;
    Ethn Dis; 2002; 12(1):S1-58-62. PubMed ID: 11913623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronary heart disease and lipid-modifying treatment in African American patients.
    Ferdinand KC
    Am Heart J; 2004 May; 147(5):774-82. PubMed ID: 15131530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
    Rubins HB; Robins SJ; Collins D; Fye CL; Anderson JW; Elam MB; Faas FH; Linares E; Schaefer EJ; Schectman G; Wilt TJ; Wittes J
    N Engl J Med; 1999 Aug; 341(6):410-8. PubMed ID: 10438259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lipid lowering therapy for primary prevention of coronary heart disease--pro lipid lowering therapy].
    Steinmetz A; Noll B; Maisch B; Schäfer JR
    Z Kardiol; 1998; 87 Suppl 2():205-9. PubMed ID: 9827484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suboptimal control of lipid levels: results from the non-interventional Centralized Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II).
    Boytsov S; Logunova N; Khomitskaya Y;
    Cardiovasc Diabetol; 2017 Dec; 16(1):158. PubMed ID: 29246151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.